Drug intelligence / Profile preview

mesothelin CAR-T

Development stage: Phase 2
Lead developer: Atara Biotherapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Intrapleural, Intraperitoneal, Intratumoral

Overview

Mesothelin CAR-T cells are a form of adoptive cell therapy that uses chimeric antigen receptors (CARs) to target mesothelin, a cell surface glycoprotein overexpressed in various solid tumors such as mesothelioma, lung, pancreas, breast, and ovarian cancers. This therapy involves engineering T cells to recognize and attack cancer cells expressing mesothelin, enhancing T-cell function and persistence. The approach aims to overcome challenges in solid tumor treatment by improving T-cell infiltration and survival within the tumor microenvironment.

Other names: mesothelin-targeted CAR-T cells

Targets

PDCD1 (Programmed cell death protein 1 receptor)Mesothelin

Beyond the preview

Go deeper on mesothelin CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mesothelin CAR-T.

Explore the full profile